Precigen announces up to $125M non-dilutive financing
Source: SeekingAlpha
2025-09-03 07:45:17 ET
More on Precigen
- Precigen, Inc. - Special Call
- Precigen: This Billion-Dollar Approval Is Still Undervalued
- Precigen: August Is Pivotal For This Biotech Innovator
- Precigen surges on FDA approval for immunotherapy
- Seeking Alpha’s Quant Rating on Precigen
Read the full article on Seeking Alpha
For further details see:
Precigen announces up to $125M non-dilutive financing
Precigen Inc.
NASDAQ: PGEN
PGEN Trading
1.53% G/L:
$3.315 Last:
1,127,054 Volume:
$3.26 Open:
PGEN Latest News
March 11, 2026 04:05:00 pm
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
January 20, 2026 08:05:00 am
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
January 12, 2026 08:00:00 am
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026 04:05:00 pm
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
PGEN Stock Data
$1,632,900,063
187,173,160
1.3%
60
N/A
Biotechnology & Life Sciences
Healthcare
US
Germantown
